Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy

^
Original-Research: Vidac Pharma Holding Plc - from Sphene Capital GmbH

29.07.2024 / 12:26 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Classification of Sphene Capital GmbH to Vidac Pharma Holding Plc

Company Name: Vidac Pharma Holding Plc ISIN: GB00BM9XQ619

Reason for the research: Update Report
Recommendation: Buy
from: 29.07.2024
Target price: EUR 4.90 (unchanged) Target price on sight of: 36 months
Last rating change: -
Analyst: Peter Thilo Hasler

Promising results of a VDA-1275 study

Vidac Pharma published promising results of its study with the active ingredient VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumours in a paper submitted to peer-review. The study shows that VDA-1275-which is being developed by Vidac Pharma as a systemic drug for the treatment of solid tumours-exhibited statistically significant efficacy as a monotherapy and synergistic effects in combination with two standard cancer therapies and also elicited an immunological response. We thereby confirm our Buy rating and our three-stage discounted cash flow entity model based price target of EUR 4.90 (base case scenario), which is based on the assumption that Vidac Pharma will get approval for its current core product VDA-1102-AK. Monte Carlo scenario values range between EUR 4.04 (10% quantile) and EUR 5.40 (90% quantile) per share.

You can download the research here: http://www.more-ir.de/d/30305.pdf

Contact for questions:
Peter Thilo Hasler, CEFA
[phone]

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

1956187 29.07.2024 CET/CEST

°

Die Vidac Pharma Holding Aktie wird zum Zeitpunkt der Veröffentlichung der Nachricht mit einem Plus von +2,22 % und einem Kurs von 0,276EUR auf Stuttgart (29. Juli 2024, 09:17 Uhr) gehandelt.

Rating: Hold
Analyst: Sphene Capital